Beam Therapeutics (BEAM) EBITDA (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of EBITDA data on file, last reported at -$96.5 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$96.5 million, up 11.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.3 million (up 82.8% YoY), and the FY2025 annual result was -$79.6 million, up 78.88% from the prior year.
• EBITDA fell to -$96.5 million in Q1 2026 per BEAM's latest filing, from $244.6 million in the prior quarter.
• Over five years, EBITDA peaked at $244.6 million in Q4 2025 and troughed at -$111.9 million in Q3 2025.
• A 5-year average of -$57.2 million and a median of -$93.8 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA sank 291.25% in 2022, then soared 502.78% in 2023.
• A 5-year view of EBITDA shows it stood at -$36.1 million in 2022, then soared by 502.78% to $145.4 million in 2023, then tumbled by 162.87% to -$91.4 million in 2024, then surged by 367.54% to $244.6 million in 2025, then tumbled by 139.45% to -$96.5 million in 2026.
• Business Quant data shows BEAM's EBITDA at -$96.5 million in Q1 2026, $244.6 million in Q4 2025, and -$111.9 million in Q3 2025.